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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the efficacy of electronic monitors, reminder devices or both, on adherence with regular inhaled medication regimes in people
with asthma.
B A C K G R O U N D
Description of the condition
Asthma is one of the most common chronic diseases in children
and adults and can be a significant cause of disability, poor qual-
ity of life and health resources utilisation among those affected.
Asthma is estimated to affect over 300 million people worldwide
(WHO 2007). The International Study of Asthma and Allergy in
Childhood found that the United Kingdom, Australia and New
Zealand had among the highest worldwide prevalence, with 15%
of children affected (Pearce2007).Global prevalence rates in adults
obtained from the cross-sectional World Health Survey (WHS)
indicated that 18.2% of adults in the UK had a clinical diagnosis
of asthmawith a 4.3%prevalence globally (To 2012). The number
of disability-adjusted life years (DALYs) lost to asthma worldwide
has been estimated to be about 15 million per year and worldwide
accounts for around 1% of all DALYs lost (GINA 2014).
Developed economies spend 1 to 2% of their health-care budget
on asthma, each patient costing between $300 and $1300 per
year. The total economic burden exceeds this when indirect costs
are taken into account (Braman 2006). In Europe, the loss of
productivity and work impairment due to asthma is estimated as
EURO9.8 billion per year (ERS 2015).
Poor adherence to maintenance inhaled corticosteroid therapy is
a challenge for those treating patients with asthma, as parental re-
porting in children and self-reporting in adults have been shown
to correlate poorly with actual use (Tashkin 1991; Bender 2000;
Burgess 2011; Patel 2013). Prescription checks are also imprecise,
merely representing the maximum that could have been taken.
In one study of 115 adults with difficult to control asthma, 65%
had sub-optimal adherence to inhaled treatment (defined as less
than 80% usage) and this correlated with reduced forced expira-
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tory volume in one second (FEV1) and higher sputum eosinophil
counts (Murphy 2012). Poor adherence to asthma therapy in both
children and adults is associated with a greater number of severe
exacerbations (Ordonez 1998;Hermosa 2010; Jentzsch 2012), in-
creased health care utilisation (Gamble 2011; McGrady 2013),
reduced quality of life (Sullivan 2013), and increased mortality
(Robertson 1992; Bergstrom 2008).
In a study of 182 adult patients with difficult-to-control asthma,
63 patients (35%) used over 50% of inhaled medications pre-
scribed over a six-month period, with 45 of those patients subse-
quently admitting poor adherence when presented with prescrip-
tion usage (Gamble 2009). Not identifying poor adherence can
lead to potentially effective medications being considered inef-
fective or doses deemed inadequate which could lead to an un-
necessary escalation of treatment in ’difficult asthma’, a condition
characterised by ongoing symptoms and/or exacerbations despite
moderate to high dose inhaled steroids and add on therapy to-
gether with appropriate education and advice. It does not imply
’severe disease’ though this may be one cause.
A qualitative study assessing the barriers to adherence found that
a lack of motivation, social barriers and simply not remembering
were common themes. Although children reported that parental
prompts to take medication were ’annoying’ they thought that
they did improve their compliance with treatment (Penza-Clyve
2004). In a cohort of 250 children, parental reporting of theirmed-
ication pattern and the feedback of pharmacy records of treatment
usage produced a modest short term improvement in adherence
but were no better than asthma education alone (Otsuki 2009).
Providing feedback of peak flow rates in children has been shown
to increase the perception of lung function and the adherence to
inhaled corticosteroids in a paediatric cohort (Feldman 2012); in
adults, monitoring inhaler usage in chronic obstructive pulmonary
disease in adults was shown to increase usage four months later
(Nides 1993).
Adherence is a complex behavioural process and there is no single
mechanism for changing adherence behaviour. Evidence suggests
that education alone may not be sufficient to bring about a sus-
tained change in adherence behaviour in asthma (Gibson 2002).
Technology now exists to monitor inhaler usage in a non-intrusive
and reliable manner rather than to rely on patient feedback as a
measure of compliance. They have opened up the possibility of
addressing the ’simply not remembering’ aspect of poor adherence
whilst also acting as a potential source of motivation knowing that
usage is being observed and may be fed back. The cost-benefits of
using electronic monitors or reminding facilities to improve ad-
herence to asthma medication is currently unclear, but they have
the potential to improve asthma control through more efficient
disease management.
Description of the intervention
Short message service (SMS) messaging (i.e. text messaging) re-
minders have been shown to be effective at increasing asthmamed-
ication usage in a cohort of adults who received a daily reminder
on their phone (Strandbygaard 2010). The difference in adher-
ence rate between this group and the controls was 17.8%, mea-
sured by dose counting on the inhaler, although no difference in
lung function was seen after 12 weeks (Strandbygaard 2010). A
Cochrane systematic review addressed the use of feedback from
mobile phone applications (“apps”) based upon self reporting of
symptoms and lung function results from two studies (Marcano
Belisario 2013). This represents a downstream intervention from
our intended study and they found insufficient evidence to advise
on such self management programmes.
Electronicmonitors and reminding facilities are twoways in which
adherence can be targeted. Electronic monitoring devices, initially
termed “nebuliser chronologs”, were first described in asthma clin-
ical practice in the 1980s (Spector 1986). They were prone to
technical problems (Gong 1988; Nides 1993), but since then have
been more successfully used to monitor treatment usage (Gibson
1995; Foster 2012; Patel 2013). They make it possible to record
medication usage and patterns of treatment. This can be of partic-
ular interest around the time of contact with health professionals
when there may be a transient increase in adherence or episodes
of ’dose dumping’ in which there may be multiple actuations of
inhalers to give the impression of longer term good adherence
(Nides 1993).
Electronic reminding facilities, as with the monitors, can also be
integrated into inhalers and have been used with some success in
the treatment of other disorders such as glaucoma (Laster 1996),
schizophrenia (Ruskin 2003), and in optimising tooth brushing
techniques (McCracken 2004). They usually combine an audio
alarm with a visual cue. The alarm sounds at designated times,
serving to remind the user to take their medication, and contin-
ues at intervals until the dose is taken. The visual cue shows the
patient whether they have delivered their medication during the
designated period. Poor technique or wilful avoidance of a medi-
cation is not monitored.
How the intervention might work
Electronic monitoring and clinician feedback enables the issue of
adherence to be discussed in an open and objective manner. For
some patients, this awareness that treatment is being monitored
will lead to increased adherence, the so-called Hawthorne effect.
Barriers to adherence are both intentional for example the patient
disagrees with diagnosis, has no concerns about their symptoms
or has concerns about the effects of inhaled steroids; or non-inten-
tional in that their are practical adherence barriers such as forget-
ting. Monitoring feedback and regular reinforced education will
address intentional barriers, and reminders will address non-in-
tentional (Horne 2002). In a cohort of 15 children aged 7 to 12
years old, a home intervention programme of asthma education
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and electronic monitoring and feedback of inhaler usage showed
that initially 28.6% used their asthma medications as prescribed,
increasing to 54.1% after a 4 week study period (Bartlett 2002).
The electronic reminders serve to prompt the user to use their in-
halers, an intervention perceived to increase adherence in children
(Penza-Clyve 2004), and reportedly increase short term adherence
in adults (Strandbygaard 2010).
We are interested in whether electronic monitoring and/or re-
minding devices can improve adherence to regular inhaled therapy
in asthma thus benefiting disease control as well as empowering
the patient to better manage their own condition through the im-
plementation of an effective self management aid.
Why it is important to do this review
Asthma is highly prevalent and optimising adherence to its treat-
mentmay improve disease control (Ordonez 1998), improve qual-
ity of life (Sullivan 2013), reduce mortality (Robertson 1992), and
have marked economic benefits by potentially curbing the unnec-
essary escalation of treatment and decreasing hospitalisation rates
in adults and children (Williams 2004; McGrady 2013).
O B J E C T I V E S
To assess the efficacy of electronic monitors, reminder devices or
both, on adherence with regular inhaled medication regimes in
people with asthma.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Wewill include published andunpublished randomised controlled
trials (RCTs), including cross-over studies, that evaluated inter-
ventions to improve adherence with inhaled asthma medication.
Types of participants
We will include any patients using regular inhaled corticosteroids
and other preventer medications that fulfil any of the internation-
ally-recognised diagnostic guidelines by the American Thoracic
Society, European Respiratory Society and Global Initiative for
Asthma. We will not apply age or gender limitations and will only
consider studies that excluded patients with significant co-mor-
bidities.
Types of interventions
We will only include trials involving objective electronic monitor-
ing of compliance of all inhalers. We will consider the following
interventions and comparators.
1. Electronic monitors with health professional feedback of
inhaler usage versus monitoring without feedback.
2. Electronic monitors with ongoing feedback from the device
versus monitoring without feedback.
3. Electronic reminders and monitors without health
professional feedback versus monitoring only without feedback.
4. Electronic reminders and monitors with health professional
feedback versus monitoring without feedback.
5. Electronic monitors and/or reminders with health
professional feedback versus an alternative intervention for
inhaler adherence e.g. education programmes, written
information, follow up support, medication training.
6. Electronic monitors and/or reminders with health
professional feedback versus monitoring without feedback.
Types of outcome measures
Primary outcomes
1. Inhaler adherence, e.g. proportion taking prescribed
medication
2. Health-related quality of life (using clinically validated
measurement tools)
3. Number of asthma exacerbations as defined by hospital
admissions or treatment with oral corticosteroids and antibiotics
or both
Secondary outcomes
1. Lung function measurement: FEV1, peak expiratory flow
rate
2. Asthma control (measured using clinically validated
questionnaires)
3. Days of missed school or work
4. Cost of interventions: cost-benefit, cost-effectiveness
5. Adverse events/side effects, barriers to effectiveness
Reporting one of more of these outcomes in the trial is not an
inclusion criterion for the review. We will assess all outcome mea-
sures at six months from the start of the study (if data is available)
and at the end of the study.
Search methods for identification of studies
Electronic searches
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We will identify trials from the Cochrane Airways Group Spe-
cialisedRegister (CAGR), which ismaintained by the Trials Search
Co-ordinator for the Group. The Register contains trial reports
identified through systematic searches of bibliographic databases
including the Cochrane Central Register of Controlled Trials
(CENTRAL), MEDLINE, EMBASE, CINAHL, AMED, and
PsycINFO, and handsearching of respiratory journals andmeeting
abstracts (please see Appendix 1 for further details). We will search
all records in the CAGR using the search strategy in Appendix 2.
We will also conduct a search of ClinicalTrials.gov (https://
clinicaltrials.gov/) and the World Health Organization (WHO)
International Clinical Trials Registry Platform (ICTRP) Search
Portal (http://apps.who.int/trialsearch/). We will search all
databases from their inception to the present, and we will impose
no restriction on language of publication.
Searching other resources
We will check reference lists of all primary studies and review ar-
ticles for additional references. We will search relevant manufac-
turers’ websites for published and unpublished trial information.
We will search for errata or retractions from included studies
published in full-text on PubMed (http://www.ncbi.nlm.nih.gov/
pubmed) and report the date this was done within the review.
Data collection and analysis
Selection of studies
Two review authors (VEC and RM) will independently screen
titles and abstracts for inclusion of all the potential studies we
identify as a result of the search and code them as ’retrieve’ (eli-
gible or potentially eligible/unclear) or ’do not retrieve’. We will
retrieve the full-text study reports/publication and two review au-
thors (VEC, and RM) will independently screen the full-text ar-
ticles and identify studies for inclusion, and identify and record
reasons for exclusion of the ineligible studies. We will resolve any
disagreement through discussion or, if required, we will consult a
third author (MLE). We will identify and exclude duplicates and
collate multiple reports of the same study so that each study rather
than each report is the unit of interest in the review. We will record
the study selection process in sufficient details to complete a Pre-
ferred Reporting Items for Systematic Reviews andMeta-Analyses
(PRISMA) flow diagram and ’Characteristics of excluded studies’
table.
Data extraction and management
We will use a data collection form for study characteristics and
outcome data which has been piloted on at least one study in
the review. Two review authors (VEC and RM) will extract study
characteristics from included studies.
We will extract the following study characteristics.
1. Methods: study design, total duration of study, details of
any ’run in’ period, number of study centres and location, study
setting, withdrawals, and date of study.
2. Participants: number of participants, mean age, age range,
gender, severity of condition, diagnostic criteria, baseline lung
function, smoking history, inclusion criteria, and exclusion
criteria.
3. Interventions: intervention, comparison, concomitant
medications, and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for trial, and notable conflicts of interest of
trial authors.
Two review authors (VEC and RM) will independently extract
outcome data from included studies. We will note in the ’Charac-
teristics of included studies’ table if outcome data was not reported
in a usable way. We will resolve disagreements by consensus or by
involving a third author (SGD). One review author (VEC) will
transfer data into the Cochrane Collaboration statistical software,
Review Manager 2014. We will double-check that data is entered
correctly by comparing the data presented in the systematic review
with the study reports. A second review author (RM) will spot-
check study characteristics for accuracy against the trial report.
Assessment of risk of bias in included studies
Two review authors (MLE and SS) will independently assess risk
of bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will resolve any disagreements by discussion or by involving
a third author (SGD). We will assess the risk of bias according to
the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We will grade each potential source of bias as high, low or unclear
and provide a quote from the study report together with a justifi-
cation for our judgment in the ’Risk of bias’ table. We will sum-
marise the risk of bias judgements across different studies for each
of the domains listed. We will consider blinding separately for dif-
ferent key outcomes where necessary (e.g. for unblinded outcome
assessment, risk of bias for all-cause mortality may be very differ-
ent than for a patient reported pain scale). Where information on
risk of bias relates to unpublished data or correspondence with a
trialist, we will note this in the ’Risk of bias’ table.
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When considering treatment effects, we will take into account the
risk of bias for the studies that contribute to that outcome.
Assesment of bias in conducting the systematic
review
We will conduct the review according to this published protocol
and report any deviations form it in the ’Differences between pro-
tocol and review’ section of the systematic review.
Measures of treatment effect
Continuous data
For continuous data, we will estimate effects of the intervention
using mean difference (MDs) and corresponding 95% confidence
intervals (CIs). If standard deviations are not reported but other
measures of population variance, such as standard errors, CIs, P
values or t values are reported, we will calculate these according
to guidance provided in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011).
Binary data
For dichotomous data, we will use risk ratios (RRs) with 95% CIs.
Multiple outcome measures
Where different scales are used to measure the same outcome,
we will use standardised mean differences (SMDs) and their 95%
CIs. If studies use different measures of effect, we will analyse and
report these separately.
We will narratively describe skewed data reported as medians and
interquartile ranges.
Unit of analysis issues
Cross-over trials
We will use data from only the first part of the study in order to
minimise potential bias from carry-over effects.
Cluster-randomised trials
Wewill analyse cluster-randomised trials in accordance withmeth-
ods described in Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011), using the average cluster size and an
estimate of the intra class correlation coefficient (ICC) to adjust
sample sizes to eh ’effective sample size’. Where the study ICC is
not available we will use external ICC estimates. We will combine
single RCTs with cluster RCTs if the designs and interventions are
considered sufficiently similar and the effect of the intervention is
unlikely to be influenced by the method of randomisation.
Multiple arm trials
Where trials have more than two arms and the variance of the dif-
ference between the comparisons of interest are not reported, we
will calculate this from the variances of all the trial arms. Where
a study includes multiple treatment arms, where relevant, we will
combine groups to create a single pair-wise comparison. Where
studies only report differences between treatment groups, as op-
posed to themean effects for each group, wewill analyse data using
the generic inverse variance function
Dealing with missing data
We will use an intention-to-treat approach and missing data will
not be imputed. Where applicable, all authors will be contacted
for missing data. We will note differential dropout between study
groups and reasons for withdrawal. Missing data will be described
in the risk of bias table and its influence on study outcomes dis-
cussed in the text. If there are enough trials, we will use sensitivity
analyses to determine the resistance of our results to the effects of
missing data.
Assessment of heterogeneity
It is likely that there will be considerable heterogeneity between
studies in terms of the precise nature of the intervention, the study
design and the outcomes. Variability may be a consequence of
clinical variation in the population, or the intervention, differences
in study quality, or random differences.
We will assess potential sources of variability as follows.
• Clinical variability: we will compare the distribution of
participants, interventions and outcomes across the included
studies and discuss and agree potential clinical heterogeneity by
consensus.
• Methodological variability: we will compare study designs
and study quality using the risk of bias criteria as outlined above
(Assessment of risk of bias in included studies).
• Statistical heterogeneity: we will analyse heterogeneity in
terms of age (preschool child (2-5 years), child (6 to 12 years),
adolescent (13-18 years), adult (19 years and older)) and severity
of asthma (defined by the Global Initiative for Asthma) (GINA
2014).
Where variability in the effects of interventions is greater than
expected by chance alone, we will evaluate statistical significance
using the Chi2 test (P≤ 0.10 for statistical significance). However,
this test may be unreliable with few/small studies or large numbers
of studies. Therefore we will also quantify the magnitude of het-
erogeneity using the I2 statistic with the following interpretation
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thresholds, based on recommendations in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011):
• 0 to 30%: might not be important;
• 31 to 50%: moderate heterogeneity;
• 51 to 75%: substantial heterogeneity;
• 76 to 100%: considerable heterogeneity.
Where data is synthesised using a random-effects model. we will
use the between-study variance ( 2) to calculate the distribution
(standard deviation) of effects across studies, as an index of hetero-
geneity. It is possible for all studies to show large consistent effects
in the face of significant heterogeneity, therefore the importance
of heterogeneity will be discussed according to the strength of ev-
idence (Chi2 and I2 statistics) and the strength of effects (magni-
tude and consistency).
Assessment of reporting biases
If there are more than 10 studies, we will explore reporting biases
and the effects of small studies using Egger’s method to test for
asymmetry in funnel plots (Egger 1997).
Data synthesis
According to the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011), for dichotomous outcomes we will
sum sample sizes and events across groups and for continuous out-
comes, we will combine means and standard deviations. We will
synthesis and report intervention comparisons separately accord-
ing to the type of data (dichotomous or continuous). Where end
of study point estimates and change from baseline are reported,
we will also analyse these separately.
If there is sufficient data, we will examine the combined effects of
interventions by pooling data using meta-analysis. Studies will be
included in meta-analyses only when the study designs, interven-
tions and outcomes are similar. Where important heterogeneity is
identified we will report the outcomes narratively in the text. It
is likely that studies will be heterogeneous therefore we will use
meta-analysis with a random-effects model. However, where there
are few studies or the effects of interventions are not randomly
distributed across studies, e.g. publication bias, random-effects es-
timates may be biased. It is likely that this review will include a
small number of low-powered studies, where meta-analysis con-
ducted using a fixed-effect model would give more reliable esti-
mates. To resolve the uncertainty over model choice we will only
pool data using meta-analysis when studies appear sufficiently het-
erogeneous and we will compare pooled data estimates from both
random-effects and fixed-effect models in the text. We will report
the mean effect estimate and its CI for both models, noting that
the CI for the random-effects model is not an estimate of hetero-
geneity (Assessment of heterogeneity). We will perform the anal-
yses using Review Manager 2014.
Summary of findings
We will create a ’Summary of findings’ table using the following
outcomes:
• inhaler adherence;
• health-related quality of life using clinically validated
measurement tools;
• number of asthma exacerbations as defined by hospital
admissions;
• lung function measurement (FEV1);
• days of missed school or work;
• cost of interventions (cost-benefit, cost-effectiveness);
• adverse events.
We will use the five Grading of Recommendations Assessment,
Development and Evaluation (GRADE) considerations (study
limitations, consistency of effect, imprecision, indirectness and
publication bias) to assess the quality of a body of evidence as it re-
lates to the studies which contribute data to the meta-analyses for
the prespecified outcomes. We will use methods and recommen-
dations described in theCochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011), using the GRADEpro (GRADE-
proGDT) software (http://www.guidelinedevelopment.org/). We
will justify all decisions to down- or up-grade the quality of studies
using footnotes and we will make comments to aid reader’s un-
derstanding of the review where necessary.
Subgroup analysis and investigation of heterogeneity
Subgroup analysis
Where comparison group sample sizes permit, we will perform the
following subgroup analyses on each intervention comparison.
1. Intervention complexity: single - as stated in intervention
comparisons; complex - where the reminder/monitoring device
is part of a multi-component intervention.
2. Age group 1: children (18 years or younger), adults (19
years or older).
3. Age group 2: preschool child (2 to 5 years), child (6 to 12
years), adolescent (13 to 18 years).
4. Severity of asthma, as defined by the Global Initiative for
Asthma (GINA 2014).
5. Follow-up duration: short term defined as less than one
month and long term meaning one year or more.
Investigation of heterogeneity
If there are sufficient numbers of studies we will manage potential
sources of heterogeneity as follows.
• Check data integrity, including measures of effect and units
of analysis.
• Explore the impact of subgroups e.g. small versus large
studies.
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• Exclude outliers, where there is a clear reason for exclusion.
We will inspect the graph and iteratively remove outlying studies
to determine whether homogeneity is restored.
Decisions will be fully discussed and reported in the review.
Sensitivity analysis
Where there are sufficient number of included studies we will
perform sensitivity analyses as follows.
• Missing data: comparing results including and excluding
studies containing outcomes with missing data.
• Risk of bias: comparing results including and excluding
studies at high risk of bias on random sequence generation and
blinding of participants.
A C K N OW L E D G E M E N T S
This protocol has been written with input from all the authors.
Chris Cates was the Editor for this review and commented criti-
cally on the review.
The background and methods section of this protocol/review is
based on a standard template used by Cochrane Airways Group.
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A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic sources
Database Frequency of search
CENTRAL (Cochrane Library) Monthly
MEDLINE (Ovid) Weekly
Embase (Ovid) Weekly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Handsearching of core respiratory conference abstracts
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Conference Years searched
American Academy of Allergy, Asthma and Immunology 2001 onwards
American Thoracic Society 2001 onwards
Asia Pacific Society of Respirology 2004 onwards
British Thoracic Society Winter Meeting 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society 1992, 1994, 2000 onwards
International Primary Care Respiratory Group Congress 2002 onwards
Thoracic Society of Australia and New Zealand 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
Asthma search
1. exp Asthma/
2. asthma$.mp.
3. (antiasthma$ or anti-asthma$).mp.
4. Respiratory Sounds/
5. wheez$.mp.
6. Bronchial Spasm/
7. bronchospas$.mp.
8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
16. or/1-15
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
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7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.
Appendix 2. Search strategy for Cochrane Airways Group Register
#1 AST:MISC1
#2 MeSH DESCRIPTOR Asthma Explode All
#3 asthma*:ti,ab
#4 #1 or #2 or #3
#5 adher*
#6 (electronic* or medication*) near3 (monitor* or reminder*)
#7 MeSH DESCRIPTOR Medication Adherence
#8 data* NEAR3 log*
#9 #5 or #6 or #7 or #8
#10 #4 and #9
{Note: in search line #1, MISC1 denotes the field in which the record is coded for condition, in this case, asthma]
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